Sorrento Therapeutics Inc (SRNE)

[dia76ca]

UPDATE! The Brazilian COVI-MSC 100 patient double blinded study of hospitalized ARDS patients IS NOW RECRUITING in 6 hospitals.
PRIMARY COMPLETION in DECEMBER 2021
FINAL COMPLETION in FEBRUARY 2022

"This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for COVID-19 infection in hospitalized subjects with acute respiratory distress syndrome.

COVI-MSC or placebo will be administered intravenously on Day 0, Day 2, and Day 4.

Acceptable standard of care treatments for COVID-19 include all approved or emergency use authorized treatments for COVID-19, even if used off-label.

Study Design

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells
Actual Study Start Date : November 16, 2021
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : February 2022